| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Our final goal is that hybrid therapy combined gene transfer via Sendai virus with bone marrow or peripheral blood cell transplantation can be completed. In this preliminary study, we investigated whether cilostazol induces improvement of blood flow in the ischemic hindlimb of mouse, and if so, examined the mechanisms of angiogenesis. Based on our results, cilostazol caused angiogenesis in ischemic hindlimb model of mouse. This angiogenesis may be due to the enhancement of nitric oxide production. Our final destination is that hybrid therapy with a combination between gene transfer via Sedai virus and cell transplantation can be established in near future.
|
